Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Lynparza (olaparib by Year
Lynparza (olaparib — AstraZeneca oncology alliance revenue) — Worldwide reported growth YoY (%) (%)
Merck Lynparza (olaparib: 11.0% in FY2025, up 2.0 pts from a year earlier.
Latest, FY2025
11.0%
Period ended Dec 31, 2025
Change on a year earlier
+2.0 pts
9.0% in FY2024
History
6 years
Since FY2019
Sources
6
Documents cited below
Where the FY2025 figure comes from
“|| Alliance Revenue – Lynparza (2) | 1,450 | 1,311 | 11 | 683 | 626 | 9 | 767 | 685 | 12”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 8-K Table 3 / 3a / 3b Product Sales.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Lynparza (olaparib — AstraZeneca oncology alliance revenue) — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11.0% | +2.0 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 9.0% | +2.0 pts | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 7.0% | – | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 36.0% | -27.0 pts | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2020 | Dec 31, 2020 | 63.0% | -74.0 pts | Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗ |
| FY2019 | Dec 31, 2019 | 137.0% | – | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
Cite this data
StockData. (2026). Merck Lynparza (olaparib (%), annual FY2019–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-lynparza-ww-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.